Compositions and methods of treating inflammatory bowel disease

Abstract

A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject.

1 - 56 . (canceled) 
     
     
         57 : A method of treating inflammatory bowel disease in a subject in need thereof, the method comprising:
 administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition comprising an immunosuppressive cell and a plurality of targeting moieties that bind to cells in the colon and small intestine of the subject, the targeting moieties being coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial, colon, and/or small intestine cell of the subject when administered to the subject systemically, wherein the cell delivery composition suppresses inflammation in the colon and small intestine of the subject.   
     
     
         58 : The method of  claim 57 , wherein the targeting moiety binds to endothelial cell adhesion molecules expressed by endothelial cells in the colon or small intestine. 
     
     
         59 : The method of  claim 58 , the endothelial cell adhesion molecule comprising an immunoglobulin superfamily cell adhesion molecule selected from the group consisting of ICAM1, ICAM2, ICAM3, VCAM1, and MadCAM. 
     
     
         60 : The method of  claim 57 , wherein the immunosuppressive cell is an immunosuppressive progenitor or stem cell. 
     
     
         61 : The method of  claim 57 , wherein the immunosuppressive cell comprises at least one of a multipotent adult progenitor cell (MAPC), multipotent adult stem cell (MASC), mesenchymal progenitor cell, or T reg  cell. 
     
     
         62 : The method of  57 , wherein the plurality of targeting moieties comprises an antibody or fragment thereof that binds to an endothelial cell adhesion molecule. 
     
     
         63 : The method of  claim 57 , wherein the cell delivery composition is administered to the subject by intravenous injection. 
     
     
         64 : The method of  57 , wherein the endothelial cell is an activated endothelial cell. 
     
     
         65 : The method of  claim 57 , wherein the immunosuppressive cell is pre-coated with a linker. 
     
     
         66 : The method of  claim 57 , wherein the linker is selected from protein G and protein A. 
     
     
         67 : The method of  claim 57 , wherein the immunosuppressive cell is directly linked to the plurality of targeting moieties. 
     
     
         68 : The method of  claim 57 , wherein the plurality of targeting moieties are modified with a lipophilic moiety. 
     
     
         69 : A method of treating inflammatory bowel disease in a subject in need thereof, the method comprising:
 administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition comprising an immunosuppressive cell and a plurality of targeting moieties that bind to cells in the colon and small intestine of the subject, the targeting moieties being coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial, colon, and/or small intestine cell of the subject when administered to the subject systemically, wherein the cell delivery composition suppresses inflammation in the colon and small intestine of the subject and the immunosuppressive cell comprises at least one of a multipotent adult progenitor cell (MAPC), multipotent adult stem cell (MASC), mesenchymal progenitor cell, or T reg  cell.   
     
     
         70 : The method of  claim 69 , wherein the targeting moiety binds to endothelial cell adhesion molecules expressed by endothelial cells in the colon or small intestine. 
     
     
         71 : The method of  claim 70 , the endothelial cell adhesion molecule comprising an immunoglobulin superfamily cell adhesion molecule selected from the group consisting of ICAM1, ICAM2, ICAM3, VCAM1, and MadCAM. 
     
     
         72 : The method of  69 , wherein the plurality of targeting moieties comprises an antibody or fragment thereof that binds to an endothelial cell adhesion molecule. 
     
     
         73 : The method of  claim 69 , wherein the cell delivery composition is administered to the subject by intravenous injection. 
     
     
         74 : The method of  69 , wherein the endothelial cell is an activated endothelial cell. 
     
     
         75 : The method of  claim 69 , wherein the immunosuppressive cell is pre-coated with a linker. 
     
     
         76 : The method of  claim 69 , wherein the linker is selected from protein G and protein A.